These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19874159)

  • 21. Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation.
    Tang CS; Chou WJ; Cheng AT
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):319-20. PubMed ID: 19519271
    [No Abstract]   [Full Text] [Related]  

  • 22. Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis.
    Camporeale A; Day KA; Ruff D; Arsenault J; Williams D; Kelsey DK
    Drug Saf; 2013 Aug; 36(8):663-71. PubMed ID: 23775507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine.
    Bangs ME; Tauscher-Wisniewski S; Polzer J; Zhang S; Acharya N; Desaiah D; Trzepacz PT; Allen AJ
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):209-218. PubMed ID: 18176331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atomoxetine-induced vocal tics in a patient with schizophrenia.
    Raveendranathan D; Rao MG; Varambally S; Venkatasubramanian G; Gangadhar BN
    J Neuropsychiatry Clin Neurosci; 2012; 24(4):E45-6. PubMed ID: 23224483
    [No Abstract]   [Full Text] [Related]  

  • 27. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
    Wehmeier PM; Dittmann RW; Schacht A; Minarzyk A; Lehmann M; Sevecke K; Lehmkuhl G
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):813-30. PubMed ID: 18315453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.
    Donnelly C; Bangs M; Trzepacz P; Jin L; Zhang S; Witte MM; Ball SG; Spencer TJ
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):176-85. PubMed ID: 20040824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent camptocormia associated with atomoxetine in a child with attention-deficit/hyperactivity disorder.
    Bhattacharya A; Praharaj SK; Sinha VK
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):596-7. PubMed ID: 25469421
    [No Abstract]   [Full Text] [Related]  

  • 32. A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Mayfield-Jorgensen ML; March JS; Kollins SH; Murray DW; Ravi H; Greenhill LL; Kotler LA; Paykina N; Biggins P; Stoner J
    J Child Adolesc Psychopharmacol; 2007 Apr; 17(2):175-85. PubMed ID: 17489712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder.
    Bangs ME; Jin L; Zhang S; Desaiah D; Allen AJ; Read HA; Regev A; Wernicke JF
    Drug Saf; 2008; 31(4):345-54. PubMed ID: 18366245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atomoxetine-induced mydriasis.
    Alhatem FJ; Decker DH
    J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):539-41. PubMed ID: 18928421
    [No Abstract]   [Full Text] [Related]  

  • 36. A case of severe akathisia with atomoxetine.
    Baweja R; Petrovic-Dovat L
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):426-7. PubMed ID: 23952192
    [No Abstract]   [Full Text] [Related]  

  • 37. Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review.
    Ercan ES; Akyol Ardic U; Kabukcu Basay B; Ercan E; Basay O
    Atten Defic Hyperact Disord; 2013 Dec; 5(4):377-85. PubMed ID: 23737214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute urinary retention associated with atomoxetine use.
    Desarkar P; Sinha VK
    Aust N Z J Psychiatry; 2006 Oct; 40(10):936. PubMed ID: 16959021
    [No Abstract]   [Full Text] [Related]  

  • 40. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Takita Y; Goto T; Ichikawa H; Saito K; Matsumoto H; Tanaka Y
    Psychiatry Clin Neurosci; 2011 Feb; 65(1):55-63. PubMed ID: 21265936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.